{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"40","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Duration of response was measured from the time measurement criteria are met for CR(complete response)/PR(partial response), whichever was first recorded, until the first date that PD(progressive disease) was objectively documented. According to the RECIST: Complete Response(CR), disappearance of all target lesions; Partial Response(PR), at least a 30% decrease in the sum of the longest diameter of target lesions; progressive disease(PD), at least a 20% increase in the sum of the longest diameter of target lesions.","dispersionType":"Full Range","groups":[{"description":"Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Carcinoma"},{"description":"Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Carcinosarcoma"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Month"}